


PRELIMINARY AMENDMENT

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

**LISTING OF CLAIMS:**

1. (currently amended): A method pharmaceutical composition for the prevention or treatment of overactive bladder accompanied with neurogenic disorders, which comprises administering an effective amount of as an active ingredient an indoline derivative represented by a formula:



wherein in the formula, R represents a saturated or unsaturated aliphatic acyl group which may have as a substituent a hydroxy group, a lower alkoxy group, a carboxy group, a lower alkoxy carbonyl group, a cycloalkyl group, an aryl group or one or more halogen atoms; a hydroxy lower alkyl group; an aliphatic acyloxyalkyl group; a lower alkyl group which has as a substituent a lower alkoxy group, a carboxy group, a lower alkoxy carbonyl group, an aryl-substituted lower alkoxy carbonyl group, a carbamoyl group, a mono or di(lower alkyl)-substituted carbamoyl group or a cyano group; an aromatic acyl group which may have as a substituent one or more halogen atoms; a furoyl group or a pyridylcarbonyl group; R¹ represents a cyano group or a carbamoyl group; R² represents a lower alkyl group which may have as a

PRELIMINARY AMENDMENT

substituent a cyano group, an aryl group or one or more halogen atoms; or a pharmaceutically acceptable salt thereof.

2. (currently amended): A method for the prevention or treatment pharmaceutical composition as claimed in claim 1, which comprises administering an effective amount of wherein the active ingredient is (-)-1-(3-hydroxypropyl)-5-((2R)-2-{[2-{(2,2,2-trifluoro-ethyl)oxy]phenyl}oxy]ethyl}amino}propyl)-2,3-dihydro-1H-indol-7- carboxamide or a pharmaceutically acceptable salt thereof.

3. (currently amended): A method for the prevention or treatment pharmaceutical composition as claimed in claim 1-~~or 2~~, wherein the neurogenic disorder is cerebral infarction, Parkinson's disease, spinal cord involvement, peripheral neurogenic disorder or multiple sclerosis.

4. (currently amended): A method for the prevention or treatment pharmaceutical composition as claimed in any of claims 1-~~or 2 to 3~~, which comprises administering is used in combination with one or more other agents used for overactive bladder accompanied with neurogenic disorder.

5. (currently amended): A method for the prevention or treatment pharmaceutical composition as claimed in claim 4 wherein the other agent used for overactive bladder accompanied with neurogenic disorder is an agent selected from an anticholinergic drug, an anti-

PRELIMINARY AMENDMENT

anxiety drug, a cholinergic drug, a cholinesterase inhibitor, an antispasmodic drug, an anti-inflammatory drug and/or an antimicrobial drug.

6. (new): A method for the prevention or treatment as claimed in claim 2, wherein the neurogenic disorder is cerebral infarction, Parkinson's disease, spinal cord involvement, peripheral neurogenic disorder or multiple sclerosis.

7. (new): A method for the prevention or treatment as claimed in claim 2, which comprises administering in combination with one or more other agents used for overactive bladder accompanied with neurogenic disorder.

8. (new): A method for the prevention or treatment as claimed in claim 3, which comprises administering in combination with one or more other agents used for overactive bladder accompanied with neurogenic disorder.

9. (new): A method for the prevention or treatment as claimed in claim 6, which comprises administering in combination with one or more other agents used for overactive bladder accompanied with neurogenic disorder.

10. (new): A method for the prevention or treatment as claimed in claim 7 wherein the other agent used for overactive bladder accompanied with neurogenic disorder is an agent

PRELIMINARY AMENDMENT

selected from an anticholinergic drug, an anti-anxiety drug, a cholinergic drug, a cholinesterase inhibitor, an antispasmodic drug, an anti-inflammatory drug or an antimicrobial drug.

11. (new): A method for the prevention or treatment as claimed in claim 8 wherein the other agent used for overactive bladder accompanied with neurogenic disorder is an agent selected from an anticholinergic drug, an anti-anxiety drug, a cholinergic drug, a cholinesterase inhibitor, an antispasmodic drug, an anti-inflammatory drug or an antimicrobial drug.

12. (new): A method for the prevention or treatment as claimed in claim 9 wherein the other agent used for overactive bladder accompanied with neurogenic disorder is an agent selected from an anticholinergic drug, an anti-anxiety drug, a cholinergic drug, a cholinesterase inhibitor, an antispasmodic drug, an anti-inflammatory drug or an antimicrobial drug.